Skye Bioscience, Inc.

SKYE Nasdaq SEC CIK 1516551
Follow Skye Bioscience Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income $69.1K +100.5% vs same quarter last year
EPS, diluted $0.01 +100.4% vs same quarter last year
Operating cash flow −$5.1M +61.6% vs same quarter last year
Operating income $26.3K +100.2% vs same quarter last year
Net income by quarter
−$9.7M
−$11.1M
−$17.6M
−$12.8M
−$14.4M
−$12.5M
−$10.8M
$69.1K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
−$60M−$40M−$20M$0$20MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearNet income
FY25−$55.9M
FY24−$26.6M
FY23−$37.6M
FY22−$19.5M
FY21−$8.5M
FY20−$6.6M
FY19-
FY18−$19.2M
FY17−$3.1M
FY16−$3.2M
FY15−$4.8M
FY14−$2.7M
FY13−$120.4K
FY12$4.5K
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$43.1M
FY24−$26.8M
FY23−$14M
FY22−$12.8M
FY21−$6.6M
FY20−$6.1M
FY19-
FY18−$3.9M
FY17−$3.4M
FY16−$3.6M
FY15−$3.7M
FY14−$1.8M
FY13−$63.6K
FY12-